澳大利亚开始试用温和的氧气疗法,用氢来增强脑癌治疗。 Australia begins trial testing mild oxygen therapy with hydrogen to boost brain cancer treatment.

澳大利亚研究人员正在发起首次临床试验,以测试1.35 ATA的轻度超压氧治疗(HBOT),加上分子氢,能否安全地改善在主动癌症治疗期间患有高等级微粒瘤的病人的治疗结果。 Australian researchers are launching a first-of-its-kind clinical trial to test whether mild hyperbaric oxygen therapy (HBOT) at 1.35 ATA, combined with molecular hydrogen, can safely improve outcomes for patients with high-grade glioma during active cancer treatment. 这项研究由100万美元捐款资助,目的是确定加压氧气疗法是否提高放射疗法的效力,减少副作用,并通过增加向缺氧肿瘤组织输送氧气来改善病人的福利。 Funded by a $1 million donation, the study aims to determine if pressurized oxygen therapy enhances radiotherapy effectiveness, reduces side effects, and improves patient well-being by increasing oxygen delivery to hypoxic tumor tissues. 与目前用于治疗后辐射伤害的HBOT不同,本次试验调查了其在治疗期间作为一种支持性治疗的作用,解决综合肿瘤学方面的一个主要证据差距。 Unlike current HBOT use for post-treatment radiation injuries, this trial investigates its role as a supportive therapy during treatment, addressing a major evidence gap in integrative oncology.